- Home
- CERO vs LRHC Comparison
CERO vs LRHC Comparison
Compare CERO & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- LRHC
- Stock Information
- Founded
- CERO 2017
- LRHC 2004
- Country
- CERO United States
- LRHC United States
- Employees
- CERO N/A
- LRHC N/A
- Industry
- CERO
- LRHC
- Sector
- CERO
- LRHC
- Exchange
- CERO Nasdaq
- LRHC Nasdaq
- Market Cap
- CERO 5.6M
- LRHC 5.4M
- IPO Year
- CERO N/A
- LRHC 2023
- Fundamental
- Price
- CERO $5.48
- LRHC $9.09
- Analyst Decision
- CERO Strong Buy
- LRHC
- Analyst Count
- CERO 2
- LRHC 0
- Target Price
- CERO $45.00
- LRHC N/A
- AVG Volume (30 Days)
- CERO 302.9K
- LRHC 43.9K
- Earning Date
- CERO 08-22-2025
- LRHC 08-18-2025
- Dividend Yield
- CERO N/A
- LRHC N/A
- EPS Growth
- CERO N/A
- LRHC N/A
- EPS
- CERO N/A
- LRHC N/A
- Revenue
- CERO N/A
- LRHC $78,037,079.00
- Revenue This Year
- CERO N/A
- LRHC N/A
- Revenue Next Year
- CERO N/A
- LRHC N/A
- P/E Ratio
- CERO N/A
- LRHC N/A
- Revenue Growth
- CERO N/A
- LRHC 54.92
- 52 Week Low
- CERO $4.27
- LRHC $4.33
- 52 Week High
- CERO $895.40
- LRHC $142.40
- Technical
- Relative Strength Index (RSI)
- CERO 31.92
- LRHC 72.25
- Support Level
- CERO $4.27
- LRHC $5.57
- Resistance Level
- CERO $7.60
- LRHC $8.11
- Average True Range (ATR)
- CERO 0.54
- LRHC 0.72
- MACD
- CERO -0.22
- LRHC 0.42
- Stochastic Oscillator
- CERO 27.85
- LRHC 84.03
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.